The recent announcement by the Department of Defense (DoD) to implement a mandatory testosterone screening program for service members, particularly those aged 30 and above, has ignited a complex debate within the medical community and among military health experts. While the stated aim is to proactively manage the health and well-being of U.S. servicemembers, the initiative, spearheaded by Defense Secretary Pete Hegseth, raises significant questions about potential unintended consequences, the scientific underpinnings of widespread screening, and the practical challenges of implementation. As a practicing urologist and health outcomes researcher with extensive experience in men’s health and population-level screening, I believe a thorough examination of the risks and benefits is paramount to ensure this program prioritizes the actual health of our military personnel.
The growing interest in testosterone therapy in recent years, fueled by direct-to-consumer marketing and online wellness trends, has outpaced a comprehensive scientific understanding of testosterone deficiency and its long-term management, especially in younger, otherwise healthy populations. The DoD’s decision to implement a broad screening mandate is unprecedented and demands careful consideration of its downstream effects.
Understanding the Endocrine System and Testosterone’s Role
Testosterone, a vital sex hormone, is orchestrated by a complex interplay of the brain and body, primarily through the hypothalamic-pituitary-gonadal (HPG) axis. This intricate system governs crucial developmental processes, from the formation of male reproductive organs in utero to the dramatic changes of puberty. Beyond reproductive functions, testosterone is also associated with certain behavioral characteristics, including aggression and sex drive.
The decline of testosterone levels with age is a well-established phenomenon, often coinciding with age-related symptoms such as increased body fat, diminished bone density (osteoporosis), and decreased libido. These symptoms can also be present in conditions affecting the hypothalamus and pituitary glands, such as certain genetic syndromes, intersex conditions, and pituitary tumors. Furthermore, lifestyle factors like obesity, sedentary behavior, and specific dietary choices can independently contribute to lower testosterone levels.
The Rise of Testosterone Therapy: A Market Explodes
These age-related changes and the potential for testosterone supplementation to mitigate them have spurred significant interest among scientists, physicians, and aging men. The global market for testosterone therapy has experienced a dramatic surge, expanding from a modest $18 million in annual sales in the late 1980s to an estimated $2 billion by 2025. This exponential growth has been largely propelled by aggressive direct-to-consumer advertising, online prescription platforms, the proliferation of wellness communities, and the influence of online personalities.
While many individuals utilizing these therapies are managed appropriately, a concerning trend has emerged: a segment of the population obtains testosterone through loosely regulated online channels, leading to instances of dangerously elevated testosterone levels far exceeding normal and safe parameters. This unregulated access and self-administration underscore the need for robust medical oversight.
Potential Benefits and Proven Risks of Testosterone Therapy
There is no doubt that testosterone replacement therapy (TRT) can yield desirable outcomes for some individuals. It has been shown to increase muscle mass, enhance libido, and, in certain cases, influence mood and behavior in ways that are perceived positively by some men. However, the medical community has long grappled with the inherent risks associated with TRT.
Early concerns about cardiovascular safety were highlighted by the Testosterone in Older Men with Mobility Limitations (TOM) study in 2010. This trial was prematurely halted due to a statistically significant higher incidence of major cardiac events, including heart attacks and strokes, among participants receiving TRT.
More recent research, such as the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) trial, published in 2023, has provided a more nuanced perspective. While the TRAVERSE trial did not replicate the heightened cardiac event rates observed in the TOM study, suggesting TRT may be no worse than placebo in terms of cardiovascular odds, it did identify a greater incidence of acute kidney injury, atrial fibrillation, and pulmonary embolism in men undergoing testosterone therapy.
Military Health Outcomes: A Deeper Dive
My own research group has been involved in evaluating health outcomes for military servicemembers, including the side effects of TRT among those covered by the military’s health insurance program, TRICARE. These Department of Defense-supported studies have revealed a higher prevalence of kidney stones and obstructive sleep apnea in military beneficiaries utilizing testosterone supplementation. Interestingly, one of these studies also indicated a significant improvement in cardiovascular disease outcomes, highlighting the complex and sometimes contradictory findings in TRT research.
Implications for Younger Service Members
For younger age groups, particularly those in the military, the implications of TRT are distinct. Defense Secretary Hegseth’s announcement specifically targets members aged 30 and older for testing. It is crucial to note that TRT can lead to a reduction in testicle size and sperm count. Both the American Urological Association and the Endocrine Society guidelines explicitly advise against testosterone use in men who plan to father children due to its adverse impact on fertility. This recommendation presents a significant consideration for a demographic that often includes individuals in their reproductive years.
The Nuances of Diagnosis and Treatment
Accurate diagnosis and appropriate management of low testosterone are critical and require a sophisticated, individualized approach. Testosterone measurements are susceptible to confounding factors and necessitate precise timing – ideally in the morning, with a confirmatory test required. Moreover, diagnosis should be supported by an assessment of other relevant markers, including complete blood counts and other hormone levels, to confirm low testosterone and identify potential underlying causes.
Furthermore, prospective patients must undergo screening for conditions that could be exacerbated by TRT. These include sleep apnea, a high risk for prostate cancer, existing heart failure or heart disease, and symptoms of thrombophilia (elevated red blood cell counts).
Once a TRT protocol is initiated, ongoing monitoring is essential to ensure treatment efficacy and to detect any adverse side effects. It is noteworthy that current Endocrine Society guidelines do not endorse routine population-level screening of asymptomatic men for hypogonadism, nor do they recommend routine supplementation for younger men presenting with low testosterone levels without specific clinical indications. These established guidelines appear to diverge from the recently announced DoD directive.
Implementing a Safe and Effective Program: Challenges and Considerations
Secretary Hegseth stated that individual servicemembers would have the autonomy to decide on testosterone supplementation if their levels are found to be low. To facilitate informed decision-making, comprehensive counseling on potential risks and benefits is indispensable. This counseling must adopt an individualized approach, taking into account patient preferences, unique physiological profiles, and, crucially, personalized monitoring for side effects and treatment response.
The logistical challenge of implementing personalized monitoring across the entire Department of Defense health system is substantial. However, it is an absolute necessity if this initiative is to be executed safely and responsibly. The widespread rollout of population-level testing in U.S. servicemembers represents a novel medical experiment without clear precedent.
Broader Impact and Future Outlook
The success and safety of this ambitious program hinge on meticulous monitoring at both the individual patient and population levels. Without this rigorous oversight, the potential for unintended negative health consequences among our servicemembers is significant.
The DoD’s initiative, while potentially aimed at enhancing readiness and well-being, necessitates a cautious and evidence-based implementation strategy. The medical community awaits further details on the specific screening methodologies, the criteria for diagnosis, the range of therapeutic options to be considered, and the robust monitoring frameworks that will be put in place. The long-term health of our military personnel depends on a commitment to scientific rigor and patient safety above all else.
Alexander Cole, M.D., is a board-certified urologist and health outcomes researcher specializing in men’s health. His work has focused on the impacts and implementation of various screening tests, including within military populations.
STAT News’s coverage of health challenges facing men and boys is supported by Rise Together, a donor-advised fund sponsored and administered by the National Philanthropic Trust and established by Richard Reeves, founding president of the American Institute for Boys and Men; and by the Boston Foundation. The financial supporters of STAT News are not involved in any editorial decisions regarding its journalism.
